Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2019

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel; Trastuzumab emtansine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PERNETTA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Jul 2013 New source identified and integrated: European Clinical Trials Database record.
    • 23 Jul 2013 Actual initiation date changed from Apr 2013 to Jul 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top